<DOC>
	<DOC>NCT01738074</DOC>
	<brief_summary>Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.</brief_summary>
	<brief_title>Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>6 to 13 weeks aged healthy baby; Guardian volunteer to participate in the study and sign informed consent; have use thermometer as required and the ability to fill in the diary table; Subjects guardian can abide by the requirements of clinical research scheme; The past has not been vaccinated rotavirus vaccine; Normal term eutocia, birth weight up to standard; Axillary temperature is 37.0 â„ƒ or less. With allergy, convulsion, epilepsy, encephalopathy and spirit history or the family history; Be allergy to any ingredients in the vaccine; Known immunology function damage or low person; Immunosuppressant therapy Accepter; Suffering from congenital malformation and developmental disorder; Known or suspected also suffer from diseases including: digestive system disease, respiratory system disease, acute infection, mother or I have HIV infection, cardiovascular diseases, malignant tumor during treatment, skin disease; Inoculation other vaccine within 7 days.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>13 Weeks</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>rotavirus</keyword>
	<keyword>trivalent genetic reassortment vaccine</keyword>
	<keyword>Phase three clinical trials</keyword>
</DOC>